Taro Pharmaceutical Industries Ltd (NYSE:TARO)
| 37.86 Delayed Data As of 3:59pm ET |  +0.04 / +0.11%Today’s Change | 22.89 Today|||52-Week Range 42.22 | +30.37% Year-to-Date |
Five Year Financial Summary
| All Currency in US Dollars | 4 Year Trend | |||||
|---|---|---|---|---|---|---|
2016 | 2017 | 2018 | 2019 | |||
| Operating Activities | Net Income / Starting Line | 541.3M | 456.7M | 210.1M | 282.1M | |
| Depreciation | 14.8M | 14.8M | 16.5M | 18.6M | ||
| Total Other Cash Flow | -11.9M | -27.6M | 33.4M | -26.4M | ||
| Funds From Operations | 532.3M | 517.6M | 316.0M | 286.6M | ||
| Funds From/For Other Operating Expenses | 137.2M | 80.1M | -7.7M | -37.2M | ||
| Net Cash Flow - Operating Activities | 395.1M | 437.5M | 323.7M | 323.8M | ||
| Investing | Increase In Investments | -220.2M | -- | -1.1B | -1.2B | |
| Decrease In Investments | -- | 196.1M | 531.4M | 1.5B | ||
| Capital Expenditures | -19.0M | -35.8M | -26.9M | -27.0M | ||
| Fixed Asset Disposal | 0.00 | 8.5M | 1.1M | 0.00 | ||
| Other Investing - Uses | -80.6M | -286.6M | -- | 0.00 | ||
| Other Investing - Sources | 35.0M | 10.0K | 396.3M | 0.00 | ||
| Net Cash Flow Investing | -284.9M | -117.8M | -241.6M | 257.1M | ||
| Financing | Short Term Borrowings | 0.00 | 0.00 | 0.00 | 0.00 | -- |
| Long Term Borrowings | 0.00 | 0.00 | 0.00 | 0.00 | -- | |
| Long Term Debt Reduction | -5.9M | 0.00 | 0.00 | 0.00 | ||
| Net Proceeds Stock Sale | 0.00 | 0.00 | 0.00 | 0.00 | -- | |
| Common Preferred Redeemed | -9.5M | -294.9M | -107.0M | -88.8M | ||
| Common Dividends | 0.00 | 0.00 | 0.00 | -500.0M | ||
| Cash Dividends Paid - Total | 0.00 | 0.00 | 0.00 | -500.0M | ||
| Other Sources - Financing | 0.00 | 0.00 | 0.00 | 0.00 | -- | |
| Other Uses - Financing | 0.00 | 0.00 | 0.00 | 0.00 | -- | |
| Net Cash Flow - Financing | -15.3M | -294.9M | -107.0M | -588.8M | ||
| Exchange Rate | Effect of Exchange Rate on Cash | 57.0K | -1.2M | 1.1M | -1.2M | |
| Net Change In Cash | 94.9M | 24.9M | -24.9M | -7.9M | ||
